DICOT Stock Overview
Engages in the development of pharmaceutical products in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Dicot Pharma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.46 |
| 52 Week High | SEK 0.58 |
| 52 Week Low | SEK 0.096 |
| Beta | 1.48 |
| 11 Month Change | 80.90% |
| 3 Month Change | 130.85% |
| 1 Year Change | 144.21% |
| 33 Year Change | -53.13% |
| 5 Year Change | -90.23% |
| Change since IPO | -94.60% |
Recent News & Updates
Shareholder Returns
| DICOT | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 14.0% | 0.9% | -0.8% |
| 1Y | 144.2% | 93.6% | 13.6% |
Return vs Industry: DICOT exceeded the Swedish Pharmaceuticals industry which returned 93.6% over the past year.
Return vs Market: DICOT exceeded the Swedish Market which returned 13.6% over the past year.
Price Volatility
| DICOT volatility | |
|---|---|
| DICOT Average Weekly Movement | 15.1% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.7% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: DICOT's share price has been volatile over the past 3 months.
Volatility Over Time: DICOT's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3 | Elin Trampe | www.dicotpharma.com |
Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It is developing LIB-01 for the treatment of erectile dysfunction and premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024.
Dicot Pharma AB Fundamentals Summary
| DICOT fundamental statistics | |
|---|---|
| Market cap | SEK 379.35m |
| Earnings (TTM) | -SEK 47.85m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.9x
P/E RatioIs DICOT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DICOT income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 47.85m |
| Earnings | -SEK 47.85m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.059 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DICOT perform over the long term?
See historical performance and comparison